Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-230
Closed -$17.4K 1846
2026
Q1
$17.4K Buy
230
+7
+3% +$526 ﹤0.01% 841
2025
Q4
$16.6K Sell
223
-8
-3% -$585 ﹤0.01% 721
2025
Q3
$15.6K Buy
231
+56
+32% +$3.72K ﹤0.01% 743
2025
Q2
$11.4K Buy
175
+165
+1,650% +$9.89K ﹤0.01% 777
2025
Q1
$618 Sell
10
-8
-44% -$530 ﹤0.01% 1185
2024
Q4
$1.3K Buy
18
+12
+200% +$937 ﹤0.01% 1049
2024
Q3
$489 Sell
6
-1
-14% -$80 ﹤0.01% 1224
2024
Q2
$520 Buy
+7
New +$525 ﹤0.01% 1189
2023
Q3
Sell
-5
Closed -$405 546
2023
Q2
$405 Hold
5
﹤0.01% 988
2023
Q1
$404 Hold
5
﹤0.01% 953
2022
Q4
$374 Sell
5
-80
-94% -$5.7K ﹤0.01% 915
2022
Q3
$5K Sell
85
-165
-66% -$11.4K ﹤0.01% 720
2022
Q2
$17K Buy
250
+180
+257% +$13.4K ﹤0.01% 565
2022
Q1
$5K Sell
70
-320
-82% -$23K ﹤0.01% 771
2021
Q4
$30K Buy
+390
New +$28.7K 0.01% 454
2021
Q3
Sell
-85
Closed -$6K 580
2021
Q2
$6K Sell
85
-60
-41% -$4.01K ﹤0.01% 732
2021
Q1
$11K Buy
+145
New +$11K ﹤0.01% 512

Other funds holding HOLX

CVA Family Office's HOLX Position: Q2 2026 in Review

CVA Family Office sold out of Hologic (HOLX) in Q2 2026, closing a stake of 230 shares — an estimated $17.4K sold.

CVA Family Office first reported a position in HOLX in Q1 2021 and held it in 17 quarters. The position peaked at $30K in Q4 2021. 3 funds tracked by Wall St. Rank hold HOLX as of Q2 2026.

  • CVA Family Office reported no remaining Hologic position as of Q2 2026 after selling out during the quarter.
  • CVA Family Office sold 230 Hologic shares in Q2 2026, an estimated $17.4K.
  • CVA Family Office first reported a position in Hologic in Q1 2021 and held it in 17 quarters.
  • CVA Family Office's Hologic position peaked at $30K in Q4 2021.
  • 3 funds tracked by Wall St. Rank held Hologic as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.